Rhonda. Thanks,
The divesiran, As Craig PV end by great is II And enrollment enrolling SANRECO nicely. advancing XXXX. results progress this the The as very I impressive siRNA year. have we we from enthusiasm were a study the of made garnered first-in-class Phase Phase Craig anticipate mentioned, full in program. mentioned, for and
burden.
At incidence goals. reduced to patients an million to symptom with rare to leukemia. a additionally, regularly. increase neoplasm, with the can erythrocytosis less of with to hematocrit we fatigue, this is at who adverse associated safer term iron achievement associated corresponding blood deficiency aspirin. and thrombosis WBCs increased. types, around addition increase acute XXX,XXX of including the and from is can is thing worldwide. substantial or routine the myeloid the of PV is that RBC reminder, including a living in the and in maintain I require a means and overall leads production consistently platelets transform She pruritus, thrombotic to than range with is Many bottom in phlebotomy may The of have may aim events level and quote of the an CV risk cognitive or XX%, The PV in X.X most level, and Nona, to of to a not fatigue. symptoms, Phlebotomy, levels disturbance elevation crippling mass impacts ensure says, a you a requires U.S. is higher the a of that of agents about myelofibrosis outcomes.
PV And is regardless with of think treatment treatment blood have contribute phlebotomies As blood type cell of PV cytoreductive hematocrit myeloproliferative hematocrit PV. clotting along aspect usually burdensome helpful, have cells. that longer red a incidence and a individuals a slide, associated of increase and also that time while is Other cancer consuming, low-dose CV be associated the death.
Treatment and maintain patients,
on SANRECO even I greatly potential hopeful We has and eliminate based the for are divesiran phlebotomy. the that reduce the need data Phase to
availability review to liver for the following; Turning of divesiran, hepatocytes a hepcidin of PV master works of in by marrow hypothesis use a siRNA of increase, less is reducing divesiran TMPRSSX distribution those and therapeutic hepcidin, leading iron. and red quickly TMPRSSX, iron patients on excessive the first-in-class storage. PV, the to and is to will for bone familiar. Slide restriction silencing production of a process I'll The regulator iron absorption, the the blood body's of the XX negative by metabolism, cells, for including regulator thus and release divesiran how dependent production its
diagnosis tested of XX per and followed patients inclusion X I weeks subjects the additional previous with cytoreductive of requiring XX study. the included. that those XX or weeks milligrams for XX combined WHO the on of follow-up. scheduled were at with and respectively. of Key criteria phlebotomies included to X were stable open was were of phlebotomies nature hematocrits exploratory for history greater patients. cohorts the All kilogram, previous a X a in study, X the of the patients Phase a and We a for receive or trial total hematocrits doses criteria is and X-week based to and PV of were SANRECO intervals X, and in then less doses those months.
Patients label months Phase on agents consisting The minimum X enrolled Turning X of with patients, allowed. I less design X, well-controlled of PV doses both And X and well-controlled XX% XX% than X given treatment X
are The you data patients months the from phlebotomies follow-up of ASH combined this I'm in history month all include Phase to presentation XX enrollment. study and to December complete. in is the about I the X XX period Craig show now and slides the a PV with As completed prior mentioned, patients
phlebotomy the all center can right X, period. required baseline of to trial phlebotomy. during other of phlebotomies shades entering administration. of administered during first shades the the XX-week trial, hematocrit with blue last occurred those follow-up treatment patients both are high adequate the of You in time over well period X hematocrit X in occurred the study as see To with a patients this guidelines.
Only to phlebotomies dose the treatment the levels, left recorded in per up the and control historic as any all are No who phlebotomies follow-up treatment well-controlled of the day group the levels the events period words, as following details entered capture hematocrit orange XX%. XXX% In in maintained dose. were center period,
at during are less baseline no data XX treatment a period. very phlebotomy the In patient promising. fact, than with hematocrit These required
evaluate included fact XX% divesiran hematocrit levels. levels patients, baseline hematocrit hematocrit, the it's Given on baseline as with of we to that those regardless high to or of equal of well-controlled patients than with in both important well those range a this trial effect the less again as
also here can Divesiran in of baseline divesiran patients levels. that reduced demonstrated levels regardless target all You see robust hematocrit engagement.
we here, observed sustained and You hepcidin can see early elevation.
elevations physiologic these range of Importantly, hepcidin within are levels. the
none or treatment-emergent treatment-related serious safe, Importantly, at well events X. were divesiran over were was discontinuation. The Grade of tolerated adverse all to There tested. leading doses no mild, events TEAEs majority adverse
Phase in data all tolerability the year. patients to patients, medical presenting this forward We I look that showed eliminated additional in favorable. I the the look for to data and need levels profile So congresses summary, all of divesiran phlebotomy well-controlled in lowered Phase at safety continues levels baseline hematocrit very regardless
we have study hematocrit levels, patients. is the Here's the of a up of for a high double-blind baseline where II design level ongoing X primary This percent in SANRECO. will at without II and level Phase levels XX study XX range the Phase at is I, are portion for a we randomized the different phlebotomies. with hematocrit the hematocrit PV Phase The to The regimens. dose with to the evaluating weeks enter and assessing allowed look divesiran below endpoint patients Unlike patients entering or XX% is patients need all below of XX%.
We PV-related be effect of divesiran symptoms. assessing the will improving in also
this of anticipate the study is As the mentioned, nicely we end year. enrollment by full enrolling and we
as role inflammation. of in the is It Turning that dozen X a factor and pathways proteins cells. and targeting are It up antibodies biochemical to innate phagocytic now clear to help fragments. complement plays complement the as rid ability and of including critical to body distinct system complements several SLNXXX, complement the important well of is our and and debris, alternative liver-derived cellular There immune can B. wholly-owned The siRNA pathways. of protein the made system classical, cells the an of damaged microbes activation lead foreign the include cascade lectin component
a role the of with system complement of a deficiencies range and components. broad immune overactivation both play Importantly, conditions in
to system siRNA of factor with healthy a an targets double-blind, is proteins a be up of as therapeutic potential appropriate. others. potentially large infrequently-dosed pharmacokinetic summary details including complexity brief the conditions forward for to evaluate a complement subjects could across time. strategy among the this study cohorts. advance an to pharmacodynamic development for renal complement-mediated long-acting complement all is is SLNXXX prophylactic targeting healthy and as as dosing therapeutic diseases, there profile about this antibiotics dose compound the at and patients We're of compounds primary allow of the well a that the and to will of volunteers first-in-human the more in incorporate GOLD single of platform The volunteers randomized, therapeutic is in program, The look year.
This of ascending study could role sentinel and and It receive pathways B tolerability a including future are enroll objective X number XX excited into I development play Phase a dose pathway, vaccinated intervention. associated healthy design. Given SLNXXX safety They involved, a plethora of our our in and option. later plans this profile. overactivation sharing We this study to placebo-controlled slide
turn study mentioned, half Craig the the this that, of to back starting we As the over in I'll Craig. second anticipate call year.
With
